Vir Biotechnology Inc logo

Vir Biotechnology Inc

VIR
Healthcare|Biotechnology|USA
$9.96
-0.38 (-3.68%)
Tangible Book
$4.89
Earnings Power
$9427.04

About

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Stock Price

+68.0%(1Y)

Pipeline Summary

35 total trials
14
Phase 1
17
Phase 2
6
Phase 3
0
Phase 4
Completed: 18Active: 7Terminated: 5Recruiting: 4NO_LONGER_AVAILABLE: 1

Active Trials (11)

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT07142811Viral Hepatitis
Phase 2Active
Enrollment: 100 participants
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06960395Solid Tumor Malignancies
Phase 1Recruiting
Enrollment: 450 participants
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
NCT05970289Chronic Hepatitis B Virus Infection
Phase 2Active
Enrollment: 86 participants
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
Phase 2Active
Enrollment: 150 participants
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07128550Viral Hepatitis
Phase 3Active
Enrollment: 150 participants
View all 11 active trials →

BioScore

4.9/10
Cautious

Ownership

Recent Insider Trades

Napolitano JanetSELL
2026-06-013,200 shares @ $9.45
Sabatini BrentSELL
2026-06-01379 shares @ $9.45
SATO VICKI LSELL
2026-05-0122,000 shares @ $10.05
De Backer MarianneSELL
2026-04-0672,559 shares @ $9.16
SATO VICKI LSELL
2026-04-0122,000 shares @ $9.07
Data last updated: Jul 13, 2026, 12:46 PM